Examples of using Combination with melphalan in English and their translations into Swedish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Official/political
-
Computer
-
Programming
-
Political
Table 1: Starting doses for thalidomide in combination with melphalan and prednisone.
When used in combination with melphalan and prednisone, Velcade is given twice a week on weeks 1, 2, 4 and 5 of a six-week treatment cycle.
Table 2: Recommended posology for Bortezomib Accord in combination with melphalan and prednisone.
Lenalidomide in combination with melphalan and prednisone followed by maintenance monotherapy in patients who are not eligible for transplant.
Recommended posology for VELCADE in combination with melphalan and prednisone for patients with previously untreated multiple myeloma Twice weekly VELCADE cycles 1-4.
Table 3: Posology modifications during subsequent cycles of Bortezomib Accord therapy in combination with melphalan and prednisone.
Thalidomide Celgene in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma,
Beromun has been studied in four main studies involving a total of 188 patients, in which it was given in combination with melphalan.
Venous thromboembolism was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone in newly diagnosed multiple myeloma.
VELCADE in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with bone marrow transplant.
Newly diagnosed multiple myeloma in patients treated with lenalidomide in combination with melphalan and prednisone.
VELCADE in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
re-initiation of therapy when VELCADE is administered in combination with melphalan and prednisone.
Bortezomib SUN in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
No dose adjustment is proposed for patients older than 75 years who are treated with lenalidomide in combination with melphalan and prednisone.
Thalidomide Celgene is used to treat multiple myeloma(a cancer of the bone marrow) in combination with melphalan and prednisone(anticancer medicines) in patients who have not been treated for multiple myeloma before.
re-initiation of therapy when VELCADE is administered in combination with melphalan and prednisone.
Among invasive SPMs, cases of MDS/AML were observed in patients receiving lenalidomide in combination with melphalan or immediately following high dose melphalan
MDS must be taken into account before initiating treatment with thalidomide in combination with melphalan and prednisone.
Venous thromboembolism was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone in newly diagnosed multiple myeloma and with monotherapy in myelodysplastic syndromes.
Overall, the safety profile of patients treated with VELCADE in monotherapy was similar to that observed in patients treated with VELCADE in combination with melphalan and prednisone.
A 2.12-fold increase in incidence rate of solid tumour SPM has been observed in patients receiving lenalidomide(9 cycles) in combination with melphalan and prednisone(1.57 per 100 person-years)
This increase was not observed in clinical trials of newly diagnosed multiple myeloma in patients taking lenalidomide in combination with low dose dexamethasone compared to thalidomide in combination with melphalan and prednisone.
Thalidomide Celgene is taken daily in treatment cycles, each cycle lasting 6 weeks, in combination with melphalan and prednisone which are taken on days 1 to 4 of each 6 week cycle.
Treatment emergent drug-related adverse reactions reported in≥ 10% of patients treated with VELCADE in combination with melphalan and prednisone Vc+M+P M+P.
The most commonly observed adverse reactions associated with the use of thalidomide in combination with melphalan and prednisone are:
The risk of occurrence of hematologic SPM must be taken into account before initiating treatment with Revlimid either in combination with melphalan or immediately following high-dose melphalan and ASCT.
the platelet count is< 25,000/μl or in combination with melphalan and prednisone when the platelet count is≤ 30,000/μl see section 4.2.
Frequencies given are based on the observations during a pivotal comparative clinical study investigating the effect of thalidomide in combination with melphalan and prednisone in previously untreated multiple myeloma patients.